Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S.
Zhang W, et al. Among authors: li j, li x.
J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366.
J Immunother Cancer. 2023.
PMID: 37730273
Free PMC article.
Clinical Trial.